Laminin γ2–mediating T cell exclusion attenuates response to anti–PD-1 therapy

Citations Over TimeTop 10% of 2021 papers

Abstract

PD-1/PD-L1 blockade therapies provide notable clinical benefits for patients with advanced cancers, but the factors influencing the effectiveness of the treatment remain incompletely cataloged. Here, the up-regulation of laminin γ2 (Ln-γ2) predicted the attenuated efficacy of anti-PD-1 drugs and was associated with unfavorable outcomes in patients with lung cancer or esophageal cancer. Furthermore, Ln-γ2 was transcriptionally activated by transforming growth factor-β1 (TGF-β1) secreted from cancer-associated fibroblasts via JNK/AP1 signaling, which blocked T cell infiltration into the tumor nests by altering the expression of T cell receptors. Coadministration of the TGF-β receptor inhibitor galunisertib and chemotherapy drugs provoked vigorous antitumor activity of anti-PD-1 therapy in mouse tumor models. Therefore, Ln-γ2 may represent a useful biomarker to optimize clinical decisions and predict the response of cancer patients to treatment with anti-PD-1 drugs.

Related Papers

• → Laminin isoforms in atherosclerotic arteries from mice and man.(2011)25 cited
• → Cell Adhesive, Protein Binding, and Antigenic Properties of Laminin(1983)27 cited
• → BASEMENT MEMBRANE PROTEINS-LAMININ AND FIBRONECTIN IN GENITO-URINARY TUMORS(1983)1 cited
• → Role of extracellular matrix on colonic cancer cell migration and proliferation(1996)
• → A BASEMENT MEMBRANE ANTIGEN ISOLATED FROM RENAL CELL CARCINOMA, AND ITS LOCALIZATION IN THE TISSUE(1984)